Treatment

FLARAXIN

Flaraxin

Treatable Diseases
video about ccc-phoenix llc and flaraxin
Chanel R1, health formula
DIAGNOSTICS
CONSULTATION
TREATMENT METHODS
RESULTS (TEXT, VIDEO)
VIDEO SEMINARS

FLARAXIN© - About medicine

III-rd AND IV-th SRAGE OF MALIGNANT NEOPLASM TREATMENT
How is it possible to bring the disease into absolute remission?

scientific data | price | consultation |questionnaire patient|

FLARAXIN-infusion is a non-toxic anti-cancer, anti-viral herbal medicine, interferogen, stimulates tumor necrosis factor, destroys tumor tissue and is working as a protector of healthy cells in case of chemotherapy. Immunomodulator and antioxidant, prevents metastatic spreading and relapse and is reducing concentration of toxins and common intoxication in the body, are safe for the application and it does not have any side effects, reduces the concentration of oncofetal proteins in the body.  

In many cases it gives regression of the tumor and destruction of metastases and metastatic process in all organs. Flaraxin prevents recurrence of the disease.

Flaraxin is compatible with other medicines, except iron containing medicines (flaraxin can bounds to Fe, and it will give neutralization). In combination treatment with the Chemotherapy and the Gama-ray therapy, flaraxin will multiply action of Chemotherapy and Gamma-ray on onco-cells and is highly reducing their toxic damage of healthy (normal) cells.

Flaraxin is efficient on I-IV stages of cancer process of malignant and non-malignant tumors (neoplasms): of brain (glioma, ependymoma, oligodendroglioma etc.); skin cancer (melanoma, basalioma etc.); lung cancer (sarcoma, adenocarcinoma and etc.); mammary cancer; cancer of the pharynx and larynx; esophageal cancer, stomach cancer (adenocarcinoma, sarcoma), colon cancer, kidney cancer, bladder cancer, prostate cancer, cancer of female reproductive organs (uterus cancer, cervix cancer, ovaries cancer); lymphogranulomathosis, blood diseases, with benign tumors (uterine fibroids, polycystosis of ovaries, mastitis, adenoma of the prostate, polyps of various organs, etc.);

If you want to buy FLARAXIN, please use the contact details at the top of the page. You can buy suppositories, tablets, capsules, balsam with or FLARAXIN-Infusions for intravenous administration. Suppositories with FLARAXIN can be used rectally or vaginally.

Head of the Department of Problems of interferon and immunomodulators – corresponding member of National Academy of Science of Ukraine, Sc.D., Professor M.Ya. Spivak

Head of the Department of Problems of interferon and immunomodulators – corresponding member of National Academy of Science of Ukraine, Sc.D., Professor M.Ya. Spivak

Interferons (IFN) are regarded to the class of cytokines and are the family of proteins, which possess antiviral, immunomodulating and antiproliferative activity. It permits to refer them as polyfunctional bioregulators of wide spectre of action. Of many years experience of IFN preparations use in clinical practice permitted to determine its effectiveness for prophylaxis and treating of viral, bacterial and some of oncological diseases. At the same time there is the other alternative way of obtaining all positive IFN effects in organism and deprivation of peculiar to IFN preparations. The idea of such approach brings to action the own interferon-productive organism system: while using interferon inductors (Flaraxin etc.). At present this method has got the name "endogenic interferongenesis". The possibility of use of such method has become obvious after IFN synthesis discovery practically by all organism cells. It is necessary to mention the fact that owing to crossing of IFN gene activation ways as well as a number of cytokines, the IFN inductors also induct tumor necrosis factor synthesis and interleikins, which play an important role in organism immunoreactiveness regulation. Thus, the broad studying of potential interferon inductors with the purpose of their instillation of the most perspective in medical practice is the actual trend of modern virology and immunology.

Sc.D., Professor Mykola Ya. SPIVAK

Scheme on FLARAXIN-Infusions | Brochure on FLARAXIN | 

The features of therapy with FLARAXIN are:

  • Good tolerability of medication FLARAXIN;

  • No side-effects with high anti-tumor activity;

  • High possibility to bring the tumor into complete regression;

  • Prevention of recurrence of the disease, destruction and prevention of metastasis;

  • The absence of toxic effects, because of the high selectivity of FLARAXIN.

FLARAXIN might be used by the patients:

  • Do not subjected to traditional treatments (which are not able to pass the surgery, chemotherapy, X-ray or Gamma therapy);

  • That are undergoing chemotherapy or radiotherapy (FLARAXIN compatible with surgery, chemotherapy, X-ray or Gamma therapy);

  • With an inoperable form of the disease;

  • That do not subjected to radiation or gamma therapy;

  • With severe allergic reaction to the administration of chemotherapeutic medications;

  • Weakened.

Here are just a few testimonies of people who have undergone treatment FLARAXIN with successful results.

Pharmacological action of FLARAXIN:

  • Bounds with oncofetal proteins and destroys them;

  • Increases the quantity of natural killers (NK-cells), T-lymphocytes;

  • Stimulates the production of endogenic interferon and tumor necrosis factor;

  • Normalize immunological background (removes immune disorders);

  • Normalizes the ratio of immune cells CD4/CD8 (helpers - suppressors).

FLARAXIN is efficient for:

  • Cerebrum (Brain) cancer (glioma, ependymoma, oligodendroglioma, nervinoma etc.);

  • Skin cancer (melanoma, melanoblastoma, skin melanoma treatment, basalioma etc.);

  • Lung cancer; (treatment of lung cancer on last stage);

  • Breast cancer;

  • Female sexual sphere cancer (uterus cancer, cervical cancer, ovaries cancer);

  • Stomach cancer;

  • Colon cancer;

  • Colorectal cancer (adenocarcinoma, carcinoma and etc.);

  • Kidneys cancer (adenocarcinoma, carcinoma and etc.);

  • Bladder cancer;

  • Pancreas cancer;

  • Mediastinal tumor;

  • Prostate cancer (adenoma, treatment of the prostate cancer);

  • Cancer of the pharynx and larynx;

  • Esophageal cancer;

  • Mediastinal cancer (tumors of the mediastinum);

  • Under non-malignant neoplasm of various localities (fibroids, myoma and etc. ).

  • Neoplastic diseases of the blood system;

  • Tumoral diseases of lymphatic system;

Efficiency of flaraxin application on different oncological diseases

FLARAXIN is not enough efficient in case of the high liver damage (more than 50%), in case of the bone cancer.

Clinical use of FLARAXIN expedient in the following cases:

1.    FLARAXIN should be used in patients with precancerous proliferative processes, as well as in patients with minimal tumor process, after radical surgical treatment when it is necessary to restore anti-tumor resistance of the organism and its homeostatic mechanisms;

2.    The treatment by FLARAXIN could be as a base or be as a background, precede chemotherapy and radiotherapy, besides it may be used in between traditional treatment cycles, and as a medication for stabilization of achieved results in the classic anticancer therapy. It is possible due to its minimal toxicity and selective action on tumor tissue;

3.    Patients with advanced neoplastic process could use FLARAXIN in the complex chemotherapy, radiotherapy, by using its specific anti-tumor activity and anti-viral, immune-stimulating properties;

4.    In case of impossibility of surgery, chemo- or radiotherapy, FLARAXIN should be used independently.

FLARAXIN is compatible with many antineoplastic medications except metal containing because it could give complex formations with iron due to his chemical properties.

FLARAXIN is reducing:

  • · Cardio toxicity, specified by lypooxigenesis activation, typical to antibiotics of antracyclic group;

  • · Neurotoxicity - like preparations of vinca-class (Vincristine, Vinblastine);

  • · Para pyramidal disorders and syndrome of “orthostatic hypotension” like Fluorouracil;

  • · Myelotoxic effect and immune depression - like alkylating preparations, etc.

FLARAXIN should be included in the next treatment schemes of patients with cancer:

Known methods of cancer treatment (chemotherapy, radiation, surgery) are accompanied by high immune suppression, which strongly inhibits the function of the immune system, closing the vicious circle of cancer process.

Chemotherapy involves the use of drugs with a variety of reactive groups, that are denaturing proteins not only the oncological cells but also normal cells, which explains their high toxicity to the body.

FLARAXIN interacts only with tumor cells, causing their death, with absolutely no effect on the blood, respiratory, digestive and excretory system, central nervous system, skin and etc. As a powerful Immunomodulator it does not suppress the immune system, and increases the level of functional activity of immune system.

In the case of the FLARAXIN appointment before chemotherapy

It is necessary to consider some of FLARAXIN features. Under the influence of FLARAXIN tumor cells become more vulnerable with respect to the factors of natural anti-tumor immunity and for the anti-tumor cytotoxic drugs. In this case FLARAXIN works as a protector of normal cells. Therefore, for a more effective treatment it is needed to prepare the original immuno-biochemical parameters of patients by FLARAXIN application, especially before start of chemotherapy.

Flaraxin should be prescribed under the low level of cytotoxic activity of natural killers (lower 40% - necessarily, 50-55% - preferably); at the presence of the initial nonprotein SH groups in the blood serum (spontaneous disproteinemia with autoimmune aggression) as well as in case of violation of redox (SH-SS) potential of serum proteins.

Often, all these violations are combined with each other. If the designated 8 injections of FLARAXIN normalized existing violations noted above, it is possible to begin chemotherapy. If on the background of positive dynamics after 8 injections have not yet reached the optimal immune-biochemical parameters, there is reason to assign additional 8 injections of FLARAXIN.

If it is impossible to carry out at least one of these immuno-biochemical tests, you can focus on the clinical picture of the treatment course of the disease. With a marked subjective improvement after first 8 injections of FLARAXIN, 8 more injections can be repeated.

It is impossible to continue FLARAXIN injections in case of individual intolerance to the medication. In such cases, the treatment scheme of the patient it is necessary to use antihistamine medication that is reducing autoimmune reaction of the body (Kenalog, Tavegil, Clemastine, Suprastinum etc.), or to provide few courses of plasmapheresis.

In the appointment of FLARAXIN after chemotherapy

FLARAXIN treatment should be administered immediately after the end of chemotherapy, especially if a reduction in the immune - biochemical parameters happened. If patient is planning to the repeat course of chemotherapy in the future, than the treatment of FLARAXIN should be prolonged till the maximum improvements of the immune- biochemical parameters. One or two FLARAXIN courses in this case are dependent on the patient's biochemical parameters that were after chemotherapy. Cancer - is immunological problem which is based on the formation of antibodies in response to complex antigens of onco associating proteins and the medical agents.

If the immuno-biochemical indicators are reduced, then the use of plasmapheresis is an important component of medical therapy and its appointment is desirable after multiple courses of chemotherapy. (As alternative of plasmapheresis it could be the application of detoxification therapy). In this case the most informative indicator is to identify the initial non-protein SH-groups in the blood serum. Their appearance indicates the necessity to use plasmapheresis.

The use of the FLARAXIN, between courses of chemotherapy, could replace the function of plasmapheresis. Because the FLARAXIN has the ability to bind with immune complexes. If the combined use of chemotherapy and FLARAXIN still gives a negative immuno - biochemical parameters (especially the non-protein - SH groups), then the use of plasmapheresis is necessary. Number of plasmapheresis sessions could varied in dependence to the immunological disorders (control is a disappearance of SH -groups). Thus, for example, fractional plasmapheresis is necessary from 5 to 10 sessions with the cleaning (during each session) up to 500 ml of blood.

The appointment of FLARAXIN enhances the effect of chemotherapy and if tolerability of the used medications is good, than reduction of their dosage is not advisable. The combination of chemotherapy and FLARAXIN in reduced dosages is advisable in patients with underlying diseases that give difficulties to do a massive chemotherapy. In severe cases of patients where  FLARAXIN were assigned, it is necessary to include in the treatment scheme the chemotherapy medication in smaller doses ( 1/5-1/10 of normal dose) in order to strengthen the impact of oncolytic action of FLARAXIN. It is desirable to appoint the chemotherapy medication that is not previously prescribed to this patient.

The duration of combined application of FLARAXIN and chemotherapy should be determined by the clinical picture and immuno-biochemical parameters of the patient. If each course is accompanied by a normalization of the latter, than prolongation of the combined application of chemotherapy and FLARAXIN is necessary. The ideal scheme can be considered as a 3-4 courses of FLARAXIN additionally to chemotherapy and 1-2 courses of FLARAXIN in the next year, after the end of chemotherapy.

It is also advisable to prescribe FLARAXIN during the dispensary observation, in case of risk factors observation (stresses, reduced immune biochemical parameters, etc.).

In the intervals between chemotherapy when it is impossible to apply FLARAXIN, the prescription of herbal medications FITOMAX is advisable. Combined their use is justified in those cases where it is supposed to do the 1st massive chemotherapy course.

Important

It is noted that the administration of medications containing plant polyphenols and dietary supplements with a high content of bioflavonoids (milk thistle, hellebore, Viola tricolor, etc.) have a negative impact on the therapeutic effect of FLARAXIN (observations are available). It is likely that in this case plays a role the degree of polyphenol compounds chemical reaction with other components (e.g., glycosylation).

The Clinical trials (studies) proved the high efficacy of FLARAXIN in the preoperative period.

Firstly, there is a significant reduction in tumor nodules, which greatly simplifies the technique of surgical intervention; secondly, FLARAXIN has strong immunomodulatory and interferonogene properties and it allows accomplish surgical intervention on a more favorable immunologic background. Thus, clinically proved is the surgery with preliminary conduction of 1-2 therapy courses of FLARAXIN.

Because of the high antimetastatic activity of FLARAXIN, it is advisable to carry out the treatment in the postoperative period (1-2 courses of FLARAXIN), and also as a prophylactics before application of chemotherapy medications with aim to reduce negative impact on normal cells.

During radiation exposure on tumor nodes we recommended the application of polyphenolic compounds of herbal origin contained in the tablets of FITOMAX series, and after end of radiation course the application of FLARAXIN intravenously. Number of FLARAXIN courses can vary widely and depends on the dynamics of cancer process and general condition of the patient.

In cases where the use of chemotherapeutic medicaments does not give positive results the application of FLARAXIN is prescribed.

The clinical trials proved a positive impact of FLARAXIN on patients, which is manifested in the improvement of their general condition, the disappearance or reduction of tumor nodules and pain, increase in the vitality and physical activity.

The efficiency of the Flaraxin is confirmed by:

INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY of NATIONAL ACADEMY OF SCIENCE OF UKRAINE (NASU)
Head of Department of Biochemical Pharmacology, corresponding member of NASU,
Honored Worker of Science and Technology, MD, professor - YURIY I. GUBSKY.

NATIONAL CANCER INSTITUTE of UKRAINE (NCI of Ukraine) 
Chief oncologist MOZU, the Director of the National Cancer Institute, MD, Professor IGOR B. SHCHEPOTIN.

DEPARTMENT of ONCOLOGY of GEORGIEVSKY MEDICAL ACADEMY of VERNADSKY CRIMEAN FEDERAL UNIVERSITY

LABORATORY OF IMMUNOLOGY AND MOLECULAR BIOLOGY of SCIENTIFIC RESEARCH INSTITUTE OF EXPERIMENTAL AND CLINICAL MEDICINE AT BOGOMOLETS NATIONAL MEDICAL UNIVERSITY (BNMU)

DEPARTMENT of PROBLEMS of INTERFERON and IMMUNOMODULATORS of DANYLO ZABOLOTNY INSTITUTE OF MICROBIOLOGY AND VIROLOGY of NASU

Kiev Medical Institute Department of Oncology,
Kiev SRI of Oncology and Radiology,
Department of Oncology of Crimean State Medical University named after S.I.Georgiyevsky,
SRI of microbiology and virusology named after D.K.Zabolotny of the National Ukrainian Academy of Sciences.

Professor Artyemov A.V. answers the questions:
(Odessa Medical Institute named after Filatov, the Department of Oncology)

1. What is Flaraxin?
2. Who is Flaraxin (read) used?
3. What is known about mechanism of Flaraxin activity? 
4. What advantages has Flaraxin in comparison with traditional methods of treatment applied in oncology? 
5. Can Flaraxin be used in patients with exposed allergy, bronchial asthma? 
6. What is the advantage of FLARAXIN in treatment of infectious diseases in comparison with the group of interferones.
7. What doses, ways, methods of treatment with Flaraxin exist? 
8. What side effects can be expected during application of Flaraxin?

1. What is Flaraxin?
Flaraxin as a powerful specific and anti-tumoral interferonogenic remedy of vegetarian origin received according to unique technology. The acting base of the preparation consists of vegetarian polyphenole compounds. Flaraxin is a lyophilized powder of yellow-brown color, well dissolved in 5% glucose so-lution, physiological solution and water.

2. Who is Flaraxin read?
Flaraxin is read under all clinic-morphological forms of malignant neoplasms, on all stages of tumoral process, non-malignant neoplasms, under inflectional and somatic diseases, accompanied by the de-velopment of secondary immune deficit, inertial viral infections of CNS, diseases, characterized by the development of autoimmune aggression.

3. What is known about mechanism of Flaraxin activity?
Flaraxin has strictly expressed specific activity relatively oncoassociated proteins in organism, causes microdenatured changes in tumoral cells causing their death with further elimination. Besides specific cancerolytic effect Flaraxin has an ability to activate production of endogenic interferon and the fact of tumoral necrosis in organism, support their high concentration during more than 72 hours. This phenomenon provides wide participation of the immune system in the fight against tumoral structures.

4. What advantages has Flaraxin in comparison with traditional methods of treatment applied in oncology?
Known methods of oncological patients treatment (chemotherapeutic, radial, surgical) are accompa-nied by powerful immune suppression that with no doubt under effectiveness of the mentioned meth-ods to the great extent suppress the function of immune system, closing vicious circle of tumoral proc-ess.
Chemotherapy foresees the use of remedies, having a number of reactionally-capable groupings, dena-turing proteins of not only tumoral, but also normal cells, that explains their high toxicity for the or-ganism.
Flaraxin contacts only with tumoral cells, causing their death, in this case it does not absolutely influ-ence hematogenesis, organs of breathing, excretory and digestive systems, CNS, skin and its append-ages. Being powerful immunomodulator, Flaraxin does not suppress immune system but vice versa rises its level of functional activity.

5. Can Flaraxin be used in patients with exposed allergy, bronchial asthma?
Yes. Flaraxin can join and lead out of the organism circulating immune complexes (CIC). According to the ability to lead CIC out of the organism Flaraxin can be equate with plasmopheresis. The use of Flaraxin in patients, suffering with allergic diseases, bronchial asthma essentially improves the state of patients of the given category.

6. What is the advantage of FLARAXIN in treatment of infectious diseases in comparison with the group of interferones.
Exposed clinical effect can be reached by the introduction of interferones (ibcluding those received recombinationally). But this therapy is passive, substitutive, that is giving ready interferon we wit-tingly promote its production in the organism. In developed countries the preparations promoting pro-duction of endogenic (personal) interferon gained a wide application, it essentially influences the price of medical methods as well as their effectiveness. Flaraxin is well combined with other preparations (antibiotics, sulfanilamides) and can be used not only in the way of mono-, but also in complex ther-apy.

7. What doses, ways, methods of treatment with Flaraxin exist?
Flsaraxin is produced in two medical forms: а) lyophilized powder for intravenous use 150 mg; б) suppositoria with flaraxin with 75mg of active substance in one suppositorium.
Clinically justified is the dose of the preparation 2 mg/kg of the patient weight.
Accounting absolute intoxicity of Flaraxin the rising of the dose twice- or three times do not cause negative reactions in the organism. Flaraxin is prescribed accounting from 16 intravenous infusions for the course of treatment. The insertion of the preparation can be done persistently (that is, during 16 days) with 10-14 days break between the courses or two half-courses of 8 days each with a week break. The break between the treatment courses comprises 10-14 days. For dose of Flaraxin correction as well as local influence on tumoral nuts Flaraxin can be used as rectal or vaginal suppositoria. Clini-cally justified is the application of suppositoria under insufficiently exposed venous net or phlebitis, developed as a result of chemotherapy application.

8. What side effects can be expected during application of Flaraxin?
During application of Flaraxin the allergic reaction can be marked very seldom, it may be connected with individual intolerance of iodocontaining preparations. During treatment of oncological patients the appearance of tiny ailement in the place of main tumoral nut or metastasis can be marked, more rarely the rise of body temperature up to subfebrile indices is marked (37,3 – 37,5°С) as a response reaction of the organism on entering of decay products of tumoral cells into the blood.

DIAGNOSTICS

Luven Diagnostic (PreICO)

Unique cancer diagnostic technology

The LUVEN screening test method created by scientist of our company detects cancer at its early stages with the accuracy of up to 96% only comparable to biopsy. None of the existing diagnostic techniques has such a high diagnostic accuracy. The LUVEN technology allows diagnosing the disease at its early stages , thus, giving a chance to thousands of people to prevent its further development.

https://luvenmed.io/

About Luven Diagnostic

The LUVEN screening test method created by scientist of our company detects cancer at its early stages with the accuracy of up to 96% only comparable to biopsy. None of the existing diagnostic techniques has such a high diagnostic accuracy.

The LUVEN technology allows to diagnose the disease at its early stages, thus, giving a chance to thousands of people to prevent its further development.

For more than 20 years the Ukrainian scientists have been developing a diagnostic method based on cyto-morphological and cyto-biophysical properties of the buccal epithelial cells. In 2004 at Fenix Cancer Research Center, they continued their research and, finally, came up and implemented an experimental method. A new method of biomaterial analysis allowed to establish a cancer diagnosis at its early stages and to assess predisposition to cancer. A great success in this medical field opened a door to new possibilities,including cancer prevention and therapy. The longstanding scientific research in this field culminated in development of The Luven diagnostic system.

Why is it critical to detect cancer in its early stage?
Around 10 mln people worldwide are annually diagnosed with cancer, with every third patient dying from it. One of the main reasons of such a high mortality rate is late diagnosis.

According to statistics:

  • after treatment in stage 1 cancer — around 93% of patients survive;

  • stage 2 cancer — around 75% survive;

  • stage 3 cancer — 55% survive;

  • stage 4 cancer — only 13% survive;

This is why one should get a check-up as often as possible, thus preventing the disease progression.

Regardless of the rapid development of modern medicine and biology cancer, annually, takes millions of human lives. One cancer patient, worldwide, dies from this disease every 30 seconds.

The key to successful cancer treatment is early diagnosis.

Our History

The development of this method started in early 1983 at the research institute, chair for genetics. Based on the cellular theory by Rudolf Vichow, a team of scientists was working on a diagnostic method and studying buccal cells. Ms. Galina Shchukina, a genetic scientist and cytologist, was at the head of the scientific research. She conducted an in-depth study of scientific papers describing a new biophysical concept of the gene activity regulation based on the role of relationship between homologous chromosomes and genome. Together with Mr. Alexander Shchukin, a nuclear physicist, they invented an ion trap allowing to estimate bioelectric charge of cells. Further research and studies of this concept laid the basis for a new diagnostic method born in 2004, according to which any changes in the human body reflect on cells, including buccal epithelial cells. It was the first milestone in the development of LUVEN a unique diagnostic and treatment system. As of today, this method allowed to collect statistical data on tests of more than twenty thousand of patients.

Why is it lucrative?

Cancer research is an acute social problem, in view of this they cast a veil on profits of medical companies. However, in-vitro diagnostics, and particularly cancer diagnostics, is a huge and most rapidly developing sector, with the potential global market of DNA cancer tests worth about $20 bn.

Unlike the majority of projects involving ICO, our company has already completed 90% of the whole thing. The sale period starts on November 15 until December 6, 2017. The token sale is planned from January 15 to February 28, 2018.

Contact person:

Manager - Bogdan Andrey
Tel: +380675717764

 

fitomax, fitomaks, ccc phoenix, Cancer Curing Center, Cancer Curing Center Feniks, Cancer Curing Center Fenix, Cancer Curing Center Phoenix, Cancer Curing Center Phoenix LLC, Flaraksin, Flaraxin, Fleraksan, Fleraxin, Floraksin, Floraxin, Floroksin, Floroxin, cccfenix, cccphoenix, fitamaks flraksin, fitamax flaraxin, fitomaks flaraxin,ivan kulik, phytamax flaraxin, phytomax flaraxin, stccc feniks, stccc fenix, stccc phoenix, stcccfeniks, stcccfenix, stcccphoenix